Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5months; p<0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients / Caffo, Orazio; Frantellizzi, Viviana; Monari, Fabio; Sbrana, Andrea; Costa, Renato Patrizio; Pinto, Carmine; Tucci, Marcello; Baldari, Sergio; Facchini, Gaetano; Bortolus, Roberto; Alongi, Filippo; Alongi, Pierpaolo; Palermo, Antonio; Fanti, Stefano; Biasco, Elisa; Murabito, Alessandra; Filice, Angelina; Zichi, Clizia; Pignata, Salvatore; Borsatti, Eugenio; Salgarello, Matteo; Spada, Massimiliano; Cortesi, Enrico; Vincentis, Giuseppe De. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 17:7(2021), pp. 807-815. [10.2217/fon-2020-0391]
Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients
Frantellizzi, VivianaSecondo
;Cortesi, EnricoPenultimo
;Vincentis, Giuseppe DeUltimo
2021
Abstract
Background: Radium 223 (RA223) is currently administered as part of a therapeutic sequence with the other life-prolonging agents (LPAs) for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: We retrospectively reviewed the clinical records of patients who had received at least three LPAs including RA223. Results: Median overall survival (OS) from the start of first-line treatment was 39.8months, with the patients who completed all six planned courses of RA223 having a longer OS than those who did not (53.2 vs 29.5months; p<0.0001). Conclusions: Our study confirms the activity of RA223 regardless of the treatment line in which it is administered and suggests that patient selection plays a central role in maximizing this activity.| File | Dimensione | Formato | |
|---|---|---|---|
|
Caffo_Sequencing radium 223_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
485.1 kB
Formato
Adobe PDF
|
485.1 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
